TMB is associated with the treatment response to immunotherapy, and elevated plasma TMB levels (≥28 Mut/Mb) have shown predictable responses to the combination therapy of PD-L1 inhibitor durvalumab and CTLA4 inhibitor tremelimumab in MSS CRC patients (37). This evidence concerns the gene CD274 and colorectal carcinoma.